| Title |
Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, August 2014
|
| DOI | 10.1007/s40257-014-0088-2 |
| Pubmed ID | |
| Authors |
Lucie Peuvrel, Brigitte Dréno |
| Abstract |
Targeted therapies have developed rapidly over the last few years in the field of oncology thanks to a better understanding of carcinogenesis. They target pathways involved in signal transduction (EGFR, HER2, HER3, HER4, FLT3, RAS, RAF, MEK, KIT, RET, mTOR, SRC, EPH, SCF), tumor angiogenesis (VEGFR, TIE2), and tumor microenvironment (PDGFR, FGFR). They rarely cause the systemic adverse reactions generally associated with chemotherapy, but frequently cause disabling and specific skin toxicity. The impact on patient quality of life can be important both in terms of symptoms caused and of potentially aesthetic consequences. Inappropriate management can increase the risk of dose reduction or discontinuation of the cancer treatment. In this review, we will discuss skin toxicity associated with the main drug classes-EGFR, BRAF, MEK, mTOR, c-KIT, CTLA4, and SMO inhibitors, and anti-angiogenic agents. Targeted therapy-induced skin toxicities will be detailed in terms of symptoms, frequency, evolution, complications, and topical and oral treatments in order to improve their diagnosis and management. |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 13% |
| Researcher | 4 | 8% |
| Student > Postgraduate | 4 | 8% |
| Student > Master | 4 | 8% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 8 | 17% |
| Unknown | 19 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 20 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2014.
All research outputs
#20,265,771
of 22,796,179 outputs
Outputs from American Journal of Clinical Dermatology
#889
of 975 outputs
Outputs of similar age
#194,364
of 231,207 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#13
of 13 outputs
Altmetric has tracked 22,796,179 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 975 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 231,207 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.